Meanwhile, the inhibition of ACAT1 strengthens the tumor-limiting activities of CD19-CAR-T cells by elevating the ratio of effector-to-target cells even under low infection rates and could rescue CD8+ T cell inhibition in chemo-immunotherapy [60, 61]. The gene discussed is CD8A; the disease is neoplasm.